This review provides an overview of the distinctive structural characteristics of KIR2DL4, followed by an examination of its expression within the immune microenvironment of tumor and the potential utility of targeting KIR2DL4 in cancer immunotherapy. The gene discussed is KIR2DL4; the disease is cancer.